Umiker et al. developed a highly efficient and selective antagonistic monoclonal antibody (JTX-8064), which could be used to block the binding of leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) to its cognate ligand, thereby allowing human TAMs to be reprogrammed to drive T-cell activation in tumors to treat cancer.229. This evidence concerns the gene LILRB2 and cancer.